Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review

Table 1 Baseline characteristics of patient population on anti-angiogenic agents

Characteristics	Anti-angiogenic agents (n = 59)
Age	64.9
Female	34 (57.62%)
Race
Caucasian	32 (54.2%)
African American	24 (40.7%)
Hispanic	3 (5.1%)
Malignancy sites
Colorectal cancer	12 (20.3%)
Hepatocellular cancer	7 (11.9%)
Ovarian cancer	6 (10.2%)
Lung	6 (10.2%)
CML/AML	5 8.5%)
Renal cell cancer	4 (6.8%)
Oropharyngeal cancer	3 (5.1%)
Uterine	2 (3.4%)
Pancreas	2 (3.4%)
Gastric cancer	2 (3.4%)
Fibrosarcoma	2 (3.4%)
Peritoneal carcinomatosis	2 (3.4%)
Cervical cancer	2 (3.4%)
Fallopian tube	1 (1.7%)
Breast cancer	1 (1.7%)
Other	2 (3.4%)
HHT/Hereditary eosinophilia
Stage of malignancy
Unstageable	9 (13.6%)
Stage I	1 (1.7%)
Stage II	3 (5.1%)
Stage III	11 (18.6%)
Stage IV	35 (59.3)

AML: Acute myeloid leukemia.

Table 2 Indication for endoscopic procedures

Indication for endoscopy (n = 86)
GI bleed	29 (33.7%)
Symptomatic (weight loss, abdominal pain, diarrhea, nausea, vomiting, obstruction)	22 (25.6%)
Anemia	5 (5.8%)
Elective diagnostic + follow-up	16 (18.6%)
Dysphagia	9 (10.5%)
Enteral access	5 (5.8%)

GI: Gastrointestinal.

Table 3 Total endoscopic procedures performed and complications

Endoscopic procedures (n = 85)
1 Esophagogastroduodenoscopy	56
(A) With biopsy	17
(B) With variceal banding	10
(C) With stent	2
(D) With pneumatic dilation	1
(E) With percutaneous gastrostomy tube placement	8
(F) Enteroscopy	1
2 Flexible sigmoidoscopy	6
(A) With biopsy	2
3 Colonoscopy	23
(A) With biopsy	7
(B) With snare	3
(C) With control of bleeding	2
(D) With stent placement	1
Complications
1 Perforation	0
2 Bleeding	2 (2.35%)
Mortality	2 (2.35%)

Table 4 List of antiangiogenic agents

Anti-angiogenic agents (n = 60)
Vascular-endothelial growth factor inhibitors
1 Bevacizumab	30
2 Ramucirumab	3
3 Lenvatinib	4
4 Sorafenib	2
Epidermal-growth factor receptor inhibitors
1 Cetuximab	3
2 Osimertinib	1
Tyrosine-kinase inhibitors
1 Lapatinib	1
2 Pazopanib	2
3 Imatinib	7
4 Dasatinib	1
5 Sunitinib	2
Mammalian target of rapamycin inhibitor
1 Everolimus	2
2 Temsirolimus	2